Spirocyclic compounds as tryptophan hydroxylase inhibitors
AssigneeRoivant Sciences GmbH
InventorsStéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
Life of this patent
Estimating the term…
Abstract
The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
Claims18
A method of treating idiopathic pulmonary arterial hypertension in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
A method of lowering peripheral serotonin in a patient having idiopathic pulmonary arterial hypertension, comprising administering to the patient in need thereof a therapeutically effective amount of (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.